Homology forms AAV manufacturing JV with Oxford; receives $130M; owns 20% of Newco

Q32 Bio Inc.

Homology receives $130M upfront from Oxford Biomedica; Oxford invests $50M additional into Newco.
Post-closing OXB owns 80% and Homology 20% of Oxford Biomedica Solutions LLC.
Tim Kelly, Homology's COO, becomes CEO and Chairman of Newco; Arthur Tzianabos on board.
Oxford Biomedica CEO John Dawson retires; Dr. Roch Doliveux named interim CEO.
Transaction expected to close Q1 2022, subject to HSR antitrust clearance.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Tim Kelly

Chief Operating Officer

QTTB · Q32 Bio Inc.

Filed: February 3, 2022, 6:59 PM ET

Effective as of the Closing, Tim Kelly will assume the role of Chief Executive Officer and Chairman of the Board of Newco and will no longer serve as the Chief Operating Officer of Homology.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tim Kelly departed as Chief Operating Officer at Q32 Bio Inc..

Action: will no longer serve
Role: Chief Operating Officer

Exact text from the filing

Effective as of the Closing, Tim Kelly will assume the role of Chief Executive Officer and Chairman of the Board of Newco and will no longer serve as the Chief Operating Officer of Homology.

View on SEC.gov

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-025957

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.